Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-022-00639-9, published online 9 May 2022.
In the version of this article initially published, the first paragraph of the “Consideration of immunotherapy” section contained incorrect hazard ratios and associated confidence intervals. “HR 1.0, 95% CI 0.57–1.74” for all patients with EGFR-mutant NSCLC has been corrected to “HR 0.60, 95% CI 0.31–1.14.” Similarly, “HR 1.22, 95% CI 0.68–2.22” for patients who had received a previous TKI has been corrected to “HR 0.74, 95% CI 0.38–1.46.” The changes have been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cooper, A.J., Sequist, L.V. & Lin, J.J. Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol 19, 744 (2022). https://doi.org/10.1038/s41571-022-00680-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00680-8
